Literature DB >> 7803795

Clonality in juvenile chronic myelogenous leukemia.

L Busque1, D G Gilliland, J T Prchal, C A Sieff, H J Weinstein, J M Sokol, M Belickova, A S Wayne, K S Zuckerman, L Sokol.   

Abstract

Juvenile chronic myelogenous leukemia (JCML) is a myeloproliferative disease in which morbidity and mortality are primarily caused by nonhematopoietic organ failure from myelomonocytic infiltration or by failure of the normal bone marrow. Morphologic evidence of maturation arrest, karyotypic abnormalities, and progression to blast crisis are infrequent events. Viral infections and other reactive processes can initially mimic the clinical course of JCML, creating diagnostic problems. Because of the rarity of JCML and technical limitations, formal clonality studies have not been reported previously. Nine female JCML patients were identified by clinical criteria, characteristic 'spontaneous' in vitro cell growth, and negative cultures and titers for various viral agents. Peripheral blood and bone marrow samples were obtained at the time of diagnosis for cell separation and RNA and DNA isolation. To assess clonality, X-chromosome inactivation patterns were evaluated using three different, recently developed polymerase chain reaction-based clonality assays. All nine female JCML patients showed evidence for monoclonal origin of mononuclear cells at the time of diagnosis. Cell separation studies further traced the monoclonal origin back to at least the most primitive myeloid progenitor cell. Reversion to a polyclonal state was demonstrated after bone marrow transplant and also in one patient following treatment with 13-cis retinoic acid. This demonstration of clonality in JCML delineates it from the reactive processes and provides a basis for molecular genetic strategies to identify causally associated mutations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7803795

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation.

Authors:  Christian Peter Kratz; Michaela Nathrath; Peter Freisinger; Petra Dressel; Hans-Peter Assmuss; Cornelia Klein; Ayami Yoshimi; Stefan Burdach; Charlotte Marie Niemeyer
Journal:  Eur J Pediatr       Date:  2005-12-21       Impact factor: 3.183

2.  Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia.

Authors:  Stefan P Tarnawsky; Michihiro Kobayashi; Rebecca J Chan; Mervin C Yoder
Journal:  J Clin Invest       Date:  2017-08-28       Impact factor: 14.808

Review 3.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

4.  Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.

Authors:  Elliot Stieglitz; Ashley F Ward; Robert B Gerbing; Todd A Alonzo; Robert J Arceci; Y Lucy Liu; Peter D Emanuel; Brigitte C Widemann; Jennifer W Cheng; Nalini Jayaprakash; Frank M Balis; Robert P Castleberry; Nancy J Bunin; Mignon L Loh; Todd M Cooper
Journal:  Pediatr Blood Cancer       Date:  2014-12-08       Impact factor: 3.167

5.  Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the β-like globin locus in juvenile myelomonocytic leukemia.

Authors:  Silvia Fluhr; Christopher Felix Krombholz; Angelina Meier; Thomas Epting; Oliver Mücke; Christoph Plass; Charlotte M Niemeyer; Christian Flotho
Journal:  Epigenetics       Date:  2017-07-27       Impact factor: 4.528

6.  Clonality assay of hematopoietic disorders: significance of the buccal epithelium as non-hematopoietic control and of 95% rejection limit as a novel criterion for monoclonality.

Authors:  H Inagaki; A Wakita; H Komatsu; M Kikuchi; A Inagaki; T Eimoto; R Ueda
Journal:  Jpn J Cancer Res       Date:  2001-12

Review 7.  Physiological and Aberrant γ-Globin Transcription During Development.

Authors:  Gloria Barbarani; Agata Labedz; Sarah Stucchi; Alessia Abbiati; Antonella E Ronchi
Journal:  Front Cell Dev Biol       Date:  2021-04-01

8.  6-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells.

Authors:  Rodica P Bunaciu; Holly A Jensen; Robert J MacDonald; Dorian H LaTocha; Jeffrey D Varner; Andrew Yen
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.